Alice Melão,  —

Scientists have developed a simple blood test that may help clinicians identify whether a person has accumulations of abnormal amyloid protein deposits in the brain — an event linked to an Alzheimer’s diagnosis. This new laboratory test may represent an alternate diagnostic tool to other expensive brain…

Targeting a single enzyme called PI3K-delta prevented neuroinflammation, reduced the accumulation of toxic amyloid-beta plaques in the brain, and prevented memory deficits in a mouse model of Alzheimer’s disease, a new study shows. This approach, which also increased the animals’ life span, may represent a potential new strategy to…

Anavex Life Sciences has launched an extension study — called ATTENTION-AD — to investigate the long-term safety and efficacy of Anavex 2-73 in delaying cognitive decline in people with early Alzheimer’s disease. Eligible patients are those now taking part in the company’s 48-week ANAVEX2-73-AD-004 study underway in…

The first two patients with Alzheimer’s disease have been dosed with Cassava Sciences’ investigational small molecule PTI-125 in a new Phase 2b clinical study. PTI-125 is a small molecule that has been designed to bind to an abnormal form of a protein called Filamin A (or FLNA),…

A modified Mediterranean-ketogenic diet can regulate bacteria in the gut that may contribute to the development and progression of cognitive impairment and Alzheimer’s disease, results from a pilot study suggest. Those findings come from a small study by researchers at Wake Forest School of Medicine, which was published in…

The small molecule inhibitor SM07883, being developed by Samumed, can effectively prevent tau protein toxic accumulation, and tau-mediated neuroinflammation in mice, data from preclinical studies show. As tau-associated mechanisms are implicated in Alzheimer’s disease, these findings suggest that SM07883 may represent a new strategy for the…

AxoSim has acquired exclusive rights to lab-grown brain miniatures, coined “Mini-Brain,” a technology developed at Johns Hopkins University that uses stem cells to create models of the human brain in a dish. The technique may help speed therapy discovery for many neurological diseases, including Alzheimer’s disease. “Acquiring rights…

Treatment with naproxen, an anti-inflammatory medication, failed to prevent the progression of Alzheimer’s in individuals at risk of developing the disease, results from a Phase 2 clinical trial show. The results, “INTREPAD: A randomized trial of naproxen to slow progress of…

The first patient has been dosed in Alkahest‘s Phase 2 clinical trial testing its investigational therapy, GRF6019, in individuals with severe Alzheimer’s disease. The study (NCT03765762) was designed to assess the safety and tolerability of the experimental treatment, as well as its impact on patients’ mental state and…

Sterubin, an active chemical compound extracted from a native California plant, was found to hold neuroprotective and anti-inflammatory potential for Alzheimer’s disease, a study shows. The study, “Old age-associated phenotypic screening for Alzheimer’s disease drug candidates identifies sterubin as a potent neuroprotective…